1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Yao, S. Norton, R.S. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C5 H9 N O3 131.130 n N-ACETYLALANINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking H2 N 16.023 AMINO GROUP non-polymer C9 H11 N O3 181.189 y TYROSINE L-peptide linking US J.Med.Chem. JMCMAR 0151 0022-2623 45 2310 2318 10.1021/jm010543z 12014969 Stabilization of the helical structure of Y2-selective analogues of neuropeptide Y by lactam bridges. 2002 To be Published 0353 Helical structure and self-association in a 13-residue neuropeptide Y Y2 receptor agonist: relationship to biological activity NE J.Biomol.NMR JBNME9 0800 0925-2738 8 379 390 Solution structure of human neuropeptide Y 1996 10.2210/pdb1d0w/pdb pdb_00001d0w 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 SYNTHETIC WITH MUTATION: L24A, I28K, I31L, T32E, A LACTAM-BRIDGE WAS INTRODUCED BETWEEN POSITIONS (28) AND (32) 1792.054 C-TERMINAL ANALOGUE OF NEUROPEPTIDE Y, A POTENT Y2 RECEPTOR AGONIST C-TERMINAL ANALOGUE L24A, I28K, I31L, T32E, A LACTAM-BRIDGE WAS INTRODUCED BETWEEN POSITIONS (28) AND (32) 1 syn polymer no yes (AYA)RHYKNLLERQRY(NH2) ARHYKNLLERQRYX A polypeptide(L) n n n n n n n n n n n n n n database_2 pdbx_nmr_exptl_sample_conditions pdbx_struct_assembly pdbx_struct_oper_list struct_conn struct_site repository Initial release Version format compliance Version format compliance Database references Derived calculations Experimental preparation 1 0 2000-06-16 1 1 2008-04-27 1 2 2011-07-13 1 3 2022-02-16 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_exptl_sample_conditions.pressure_units _struct_conn.details _struct_conn.pdbx_dist_value _struct_conn.pdbx_leaving_atom_flag _struct_conn.ptnr1_auth_comp_id _struct_conn.ptnr1_auth_seq_id _struct_conn.ptnr1_label_atom_id _struct_conn.ptnr1_label_comp_id _struct_conn.ptnr1_label_seq_id _struct_conn.ptnr2_auth_comp_id _struct_conn.ptnr2_auth_seq_id _struct_conn.ptnr2_label_atom_id _struct_conn.ptnr2_label_comp_id _struct_conn.ptnr2_label_seq_id _struct_site.pdbx_auth_asym_id _struct_site.pdbx_auth_comp_id _struct_site.pdbx_auth_seq_id RCSB Y RCSB 1999-09-14 REL REL Chemically synthesized. sample THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR TECHNIQUES. structures with the lowest energy 100 20 2D TOCSY 2D NOESY DQF-COSY 5.0 1 atm 308 K THE STRUCTURE WAS CALCULATED USING A TOTAL OF 124 UPPER BOUND DISTANCE RESTRAINTS AND 8 BACKBONE DIHEDRAL ANGLE CONSTRAINTS simulated annealing 1 closest to the average 3.5 MG IN 0.6 ML H2O CONTAINING 30% TFE-D3 (BY VOLUME) BRUKER collection XEASY 2.1 BARTELS data analysis XEASY 1.3 BRUNGER structure solution X-PLOR 3.85 BRUNGER refinement X-PLOR 3.85 600 Bruker DRX 500 Bruker AMX ALA 24 n 1 AYA 24 A ARG 25 n 2 ARG 25 A HIS 26 n 3 HIS 26 A TYR 27 n 4 TYR 27 A LYS 28 n 5 LYS 28 A ASN 29 n 6 ASN 29 A LEU 30 n 7 LEU 30 A LEU 31 n 8 LEU 31 A GLU 32 n 9 GLU 32 A ARG 33 n 10 ARG 33 A GLN 34 n 11 GLN 34 A ARG 35 n 12 ARG 35 A TYR 36 n 13 TYR 36 A NH2 37 n 14 NH2 37 A author_defined_assembly 1 monomeric A AYA 24 N-ACETYLALANINE A AYA 1 ALA 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 4 -3.20 0.50 120.30 117.10 A A A NE CZ NH2 ARG ARG ARG 33 33 33 N 9 -3.29 0.50 120.30 117.01 A A A NE CZ NH2 ARG ARG ARG 33 33 33 N 12 -3.04 0.50 120.30 117.26 A A A NE CZ NH2 ARG ARG ARG 25 25 25 N 19 -3.62 0.50 120.30 116.68 A A A NE CZ NH2 ARG ARG ARG 33 33 33 N 20 -3.88 0.60 121.00 117.12 A A A CB CG CD2 TYR TYR TYR 36 36 36 N 20 3.71 0.60 121.00 124.71 A A A CB CG CD1 TYR TYR TYR 36 36 36 N 1 A A NE2 CD2 HIS HIS 26 26 -0.066 0.011 1.373 1.307 N 3 A A NE2 CD2 HIS HIS 26 26 -0.067 0.011 1.373 1.306 N 4 A A NE2 CD2 HIS HIS 26 26 -0.066 0.011 1.373 1.307 N 5 A A NE2 CD2 HIS HIS 26 26 -0.066 0.011 1.373 1.307 N 6 A A NE2 CD2 HIS HIS 26 26 -0.066 0.011 1.373 1.307 N 7 A A NE2 CD2 HIS HIS 26 26 -0.067 0.011 1.373 1.306 N 8 A A NE2 CD2 HIS HIS 26 26 -0.066 0.011 1.373 1.307 N 9 A A NE2 CD2 HIS HIS 26 26 -0.067 0.011 1.373 1.306 N 11 A A NE2 CD2 HIS HIS 26 26 -0.069 0.011 1.373 1.304 N 12 A A NE2 CD2 HIS HIS 26 26 -0.067 0.011 1.373 1.306 N 13 A A NE2 CD2 HIS HIS 26 26 -0.067 0.011 1.373 1.306 N 14 A A NE2 CD2 HIS HIS 26 26 -0.068 0.011 1.373 1.305 N 15 A A NE2 CD2 HIS HIS 26 26 -0.066 0.011 1.373 1.307 N 18 A A NE2 CD2 HIS HIS 26 26 -0.067 0.011 1.373 1.306 N 19 A A NE2 CD2 HIS HIS 26 26 -0.066 0.011 1.373 1.307 N 20 A A NE2 CD2 HIS HIS 26 26 -0.068 0.011 1.373 1.305 N 1 A HIS 26 -107.86 47.52 1 A TYR 27 -135.39 -65.02 2 A HIS 26 -117.68 63.84 2 A LEU 30 -102.47 -62.84 2 A GLN 34 -35.96 -36.80 2 A ARG 35 -101.93 51.85 3 A TYR 27 -132.94 -60.24 3 A LEU 30 -100.93 -61.19 3 A GLN 34 -87.94 33.89 4 A HIS 26 -108.23 41.14 4 A LEU 30 -102.93 -67.00 5 A ARG 25 -22.05 -49.44 5 A TYR 27 -100.54 -67.36 5 A ASN 29 -47.04 -11.22 5 A LEU 30 -101.00 -62.70 5 A GLU 32 -99.92 34.24 5 A GLN 34 -24.38 -53.02 6 A ARG 25 -101.20 -62.48 6 A HIS 26 -109.15 68.52 6 A TYR 27 -110.46 -74.80 7 A TYR 27 -125.93 -66.16 7 A LEU 30 -101.01 -60.03 7 A GLN 34 -25.20 -71.55 8 A ARG 25 -111.68 -79.55 8 A HIS 26 -91.99 55.40 8 A ASN 29 -47.27 13.55 8 A GLU 32 -97.12 30.79 9 A HIS 26 -3.18 64.65 9 A TYR 27 -127.98 -59.75 9 A ASN 29 -36.76 -37.96 9 A ARG 35 -95.24 50.01 10 A ARG 25 -98.12 -67.31 10 A ASN 29 -46.50 11.14 10 A GLN 34 -100.81 -68.15 11 A TYR 27 -17.07 -59.00 12 A ARG 25 -23.94 -53.68 12 A TYR 27 -123.47 -62.93 12 A ASN 29 -65.92 25.48 12 A LEU 30 -101.12 -60.35 12 A ARG 35 -109.09 41.45 13 A ARG 25 15.13 -57.61 13 A TYR 27 -105.96 -63.38 13 A ASN 29 -62.16 14.67 13 A ARG 33 -100.77 -61.37 13 A GLN 34 -19.34 -55.20 13 A ARG 35 -148.76 43.14 14 A HIS 26 -93.84 40.74 14 A ASN 29 -47.85 -14.96 14 A GLN 34 -20.06 -34.95 15 A ASN 29 -64.16 0.18 15 A GLN 34 -19.58 -61.89 15 A ARG 35 171.98 44.20 16 A ARG 25 -15.62 -54.95 16 A TYR 27 -125.37 -58.59 16 A ASN 29 -57.96 -8.58 16 A LEU 30 -102.38 -61.13 16 A ARG 35 -115.18 56.75 17 A ARG 25 -124.77 -50.01 17 A HIS 26 -107.43 78.85 17 A TYR 27 -145.79 -64.13 17 A ASN 29 -47.91 -3.50 17 A GLU 32 -91.11 32.09 17 A ARG 33 -102.87 -65.70 17 A GLN 34 -18.75 -63.89 17 A ARG 35 -145.12 51.37 18 A ARG 25 -105.62 -75.71 18 A GLN 34 -19.92 -66.24 19 A ARG 25 -120.31 -55.97 19 A TYR 27 -141.87 -75.52 19 A ASN 29 -59.21 10.19 19 A ARG 33 -100.02 -67.78 20 A ARG 25 -130.17 -63.42 20 A ASN 29 -69.94 2.91 20 A LEU 30 -102.62 -63.16 20 A GLN 34 -20.70 -64.94 20 A ARG 35 -140.71 44.99 SOLUTION STRUCTURE OF LACTAM-BRIDGED C-TERMINAL ANALOGUE-I OF NEUROPEPTIDE Y 1 N N A TYR 27 A TYR 4 HELX_P A GLU 32 A GLU 9 1 1 6 covale 1.311 both A AYA 24 A C AYA 1 1_555 A ARG 25 A N ARG 2 1_555 covale LACTAM-BRIDGE WAS INTRODUCED 1.311 none A LYS 28 A NZ LYS 5 1_555 A GLU 32 A CD GLU 9 1_555 covale 1.298 both A TYR 36 A C TYR 13 1_555 A NH2 37 A N NH2 14 1_555 NEUROPEPTIDE LACTAM-BRIDGED, HELIX, NEUROPEPTIDE 1D0W PDB 1 1D0W 24 37 1D0W 24 37 1D0W A 1 1 14 BINDING SITE FOR RESIDUE NH2 A 37 A NH2 37 Software 2 A ARG 35 A ARG 12 2 1_555 A TYR 36 A TYR 13 2 1_555 1 P 1